---
schema_version: "secwatch.filing_event.v1"
accession: "0000914121-22-000084"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:07:20.641638+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS

## Summary
- Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.
- GAAP net loss $8.4M (-$0.21/share) vs loss $4.3M (-$0.11) a year ago; adjusted loss per share $0.02.
- Gross margin 51.8%, down 340 bps due to supply chain, labor shortages, raw material/freight costs.
- FY2022 revenue guidance reaffirmed $310-315M; gross margin cut to 52-54% from 55%; adj. EPS guidance to ($0.02)-$0.02.
- Full market release of AlphaVac Thrombectomy device commenced after quarter end.

## SEC filing metadata
- accession: 0000914121-22-000084
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/0000914121-22-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/p57239050-8ki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914121-22-000084
- JSON: https://secwatch.observer/filing/0000914121-22-000084.json
- Plain text: https://secwatch.observer/filing/0000914121-22-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.